Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Posts Surge in Q1 Revenues, Narrowed Losses

NEW YORK, April 20 (GenomeWeb News) - Illumina today reported a 153 percent increase in revenues for its first fiscal quarter of 2004, accompanied by narrowed losses.

For the quarter ended March 28, 2004, Illumina posted revenue of $10.8 million, up sharply from $4.3 million for the same period in 2003. Product revenue was $8.9 million for the quarter, up from $1.4 million in the first quarter 2003, while service revenue dipped slightly, to $1.2 million, from $1.9 million in the same period last year.

The company's net loss for the quarter was $3.9 million, or $0.12 per share, compared to $9.0 million, or $0.28 per share, in the first quarter of 2003.

Illumina reported $5.2 million in R&D expenses for the first quarter of 2004, down from $5.7 million in the same period of 2003.

Illumina's cash and investments as of March 28, 2004, were $27.9 million, compared to $32.9 million at the end of 2003. The company said that its cash holdings, including long-term restricted investments, totaled $40.0 million at the end of the quarter.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.